Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » FDA Eases Regulatory Path, Consumer Access to Genetic Health Risk Tests

FDA Eases Regulatory Path, Consumer Access to Genetic Health Risk Tests

Nov 06, 2017
|
staff reporter

NEW YORK (GenomeWeb) – The US Food and Drug Administration today announced it is easing the path for manufacturers who want to sell genetic health risk tests directly to consumers. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Shift in Regulation

An announcement last week says laboratory-developed tests do not need to undergo premarket review by FDA.

Trump on FDA

As the Washington Post reports, President Donald Trump has made unfounded accusations against the FDA, saying it is part of the "deep state" and purposely causing delays.

More, But Less

The Associated Press reports India has boosted its COVID-19 testing ability, but may rely too much on antigen tests.

PLOS Papers on Co-Cultured Pathogen Transcripts, Hantaan Virus Diversity, Sudden Cardiac Death Variants

In PLOS this week: "dual-seq" transcriptomic analysis of bacterial cultures, genetic diversity among Hantaviridae, and more.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Regulatory News & FDA Approvals

  1. Streck Gets FDA De Novo Clearance for Blood Collection Tube With Guardant Health Liquid Biopsy Assay

  2. HHS Move Upends FDA Role in Laboratory-Developed Test Regulation

    Premium

  3. HHS Says FDA Can't Regulate Lab-Developed Tests Without Notice, Comment Rulemaking

  4. 23andMe Garners FDA Clearance for CYP2C19 PGx Test Report

  5. Antegenes Receives CE Marks for Cancer, Melanoma Polygenic Risk Score Tests

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.